Influence of the 2016 smarter medicine campaign on sedative prescriptions in older adults in Swiss university hospitals: a LUCID NDS study



M. Débieux^{1,2}, J. Regina^{1,3}, M. Altarelli^{1,3}, P. Rolland^{4,5}, A. Mari^{4,5}, F. Amato^{4,5}, D. Brüggemann^{4,5}, T. Guffi⁶, J. Ehrsam^{7,8}, J.-L. Reny⁹, J. Stirnemann⁹, F. Vallelian⁶, C.A. Meier⁶, D. Aujesky¹⁰, C.E. Aubert^{10,11}, C. Lovis^{7,8}, G. Obozinski^{4,5}, M. Méan³ & LUCID Consortium

¹University of Lausanne (UNIL), Lausanne, Suisse. ²HFR Riaz, General Internal Medicine, Riaz, Suisse. ³Lausanne University Hospital (CHUV), Lausanne, Suisse. ⁴Swiss Data Science Center (SDSC), Lausanne, Suisse. ⁵École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Suisse. ⁶Universitätsspital Zürich, Division of Internal Medicine, Zürich, Suisse. ¹Geneva University Hospitals, Division of Medical Information Sciences, Diagnostic department, Geneva, Suisse. ⁰University of Geneva, Department of Radiology and Medical Informatics, Geneva, Suisse. ⁰Hôpitaux Universitaires Genève (HUG), Division of General Internal Medicine, Geneva, Suisse. ¹¹University of Bern, Institute for Primary Healthcare, Bern, Suisse

Background

Smarter Medicine published its first list of recommendations for medical inpatients in 2016. It classified the prescription of benzodiazepines (BZD) and other sedatives in adults aged ≥65 years as "low-value care" (LVC) due to its association with various complications, such as prolonged hospital stays and falls. This study aimed to determine whether the publication was followed by a reduction in BZD and other sedative prescriptions in older adults in Swiss university hospitals.

Methods

Observational, multicentric, before-and-after study using data from the LUCID NDS on general internal medicine (GIM) hospitalisations. The study included consenting adult patients aged ≥65 years who were hospitalised for at least 24 hours in Lausanne, Geneva, Bern, and Zurich university hospitals between 01.01.2014 and 05.02.2024. Basel was excluded due to insufficient data before 2018. The publication period, from 01.05.2016 to 30.11.2016, separated the before- and afterpublication periods. Additionally, the three COVID-19 waves were excluded. The presence of at least one prescription of BZD or other sedatives, such as Z-drugs and barbiturates, during a hospital stay in patients without alcohol dependence, epilepsy, or psychiatric comorbidities (identified using ICD-10 codes) was classified as LVC. We assessed the proportion of such LVC before and after the publication.

Results

Among 58,554 total stays, 17.5% (N=10,275) occurred before 01.05.2016. Patient characteristics are shown in the **Table**. Overall, inappropriate BZD or other sedative prescriptions occurred in 20.5% (N=12,021) of stays. Among BZD, lorazepam was the most frequently prescribed, accounting for 35.1% of LVC prescriptions, while Z-drugs comprised 27.1%. The proportion of LVC decreased from 30.4% before publication to 18.4% after publication across participating hospitals (**Figure**).

Conclusion

Over the last decade, BZD or other sedatives were prescribed in approximately one in five hospital stays for adults aged ≥65 years. We observed a 12% decrease in these LVC prescriptions in Swiss university hospitals following the publication of the smarter medicine recommendation in 2016. Efforts must continue to strengthen this positive trend.

Table: Comparison of characteristics of patients within included stays.




Figure: Number of stays and proportion of inappropriate BZD or other sedatives prescriptions over time. Stays increased from 2016 due to the adoption of general consents in hospitals.

